Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 101 to 150 of 175 results for cognitive behaviour therapy

  1. Endoscopic thoracic sympathectomy for primary facial blushing (HTG331)

    Evidence-based recommendations on endoscopic thoracic sympathectomy for primary facial blushing. This involves cutting off nerve signals to stop the blushing.

  2. What is the clinical and cost effectiveness of psychological therapies for children and young people who have tinnitus-related distress?

    The evidence suggests that cognitive behavioural therapy (CBT), mindfulness-based CBT and acceptance and...

  3. Head injury: assessment and early management (NG232)

    This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.

  4. Brain tumours (primary) and brain metastases in over 16s (NG99)

    This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.

  5. NICE health technology evaluation topic selection: the manual (PMG37)

    This manual sets out the process for deciding how topics are identified, selected and routed for NICE guidance developed by the Centre for Health Technology Evaluation (CHTE). This includes diagnostics, highly specialised technologies, interventional procedures, medical technologies and technology appraisal guidance

  6. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of psychological therapies in children aged 5 to 11 years with mild or moderate to severe depression?

    11‑year‑olds with moderate to severe depression, family-based IPT and family therapy were more effective at reducing depression symptoms...

  7. Pelvic floor dysfunction: prevention and non-surgical management (NG210)

    This guideline covers the prevention, assessment and non-surgical management of pelvic floor dysfunction in women aged 12 and over. It aims to raise awareness and help women to reduce their risk of pelvic floor dysfunction. For women who have pelvic floor dysfunction, the guideline recommends interventions based on their specific symptoms.

  8. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

  9. Implanted vagus nerve stimulation for treatment-resistant depression (HTG551)

    Evidence-based recommendations on vagus nerve stimulation for treatment-resistant depression in adults. This involves implanting an electrical stimulator under the skin of the chest and connecting it by wires to the vagus nerve.

  10. Epilepsies in children, young people and adults (NG217)

    This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.

  11. What is the clinical and cost effectiveness of psychological therapies for people who are d/Deaf or who have a severe-to-profound hearing loss and tinnitus-related distress?

    tinnitus-related distress? Any explanatory notes(if applicable) CBT is a psychological therapy that is usually delivered to...

  12. What is the clinical and cost effectiveness of psychological intervention alone, compared with antipsychotic medication and compared with psychological intervention and antipsychotic medication combined, in young people with first episode psychosis?

    interventions most likely to have an impact is family intervention and individual CBT. The key outcomes should include symptoms, relapse...

  13. Cerebral palsy in adults (NG119)

    This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.

  14. People who choose not to take antipsychotic medication:- What is the clinical and cost effectiveness of psychological intervention alone, compared with treatment as usual, in people with psychosis or schizophrenia who choose not to take antipsychotic medication?

    or lack of efficacy. There is evidence that psychological interventions (CBT and family intervention) as an adjunct to antipsychotic...

  15. Mental wellbeing of older people in care homes (QS50)

    This quality standard covers the mental wellbeing of older people (aged 65 and over) receiving care in care homes (including residential and nursing accommodation, day care and respite care). It focuses on support for people to improve their mental wellbeing so that they can stay as well and independent as possible. It describes high-quality care in priority areas for improvement.

  16. Combined interventions for adults with social anxiety disorder:- What is the clinical and cost effectiveness of combined psychological and pharmacological interventions compared with either intervention alone in the treatment of adults with social anxiety disorder?

    Why this is important:- There is evidence for the effectiveness of both CBT and medication, in particular SSRIs, in the treatment of...

  17. Medicines associated with dependence or withdrawal symptoms. Patient decision aid full version on should I stop my benzodiazepine or z-drug?

    They may also suggest you think about group cognitive behavioural therapy (CBT). This is a talking therapy. It...

  18. Smoking: reducing and preventing tobacco use (QS82)

    This quality standard covers reducing and preventing tobacco use in adults, young people and children. It includes interventions to discourage people from taking up smoking, tobacco control strategies and smokefree policies. It is particularly relevant to local authorities, schools and colleges, employers and NHS service providers. It describes high-quality care in priority areas for improvement.

  19. Learning disability: identifying and managing mental health problems (QS142)

    This quality standard covers the prevention, assessment and management of mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It also covers family members, carers and care workers.

  20. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

  21. Science policy and methods projects

    Science policy projects with NICE.

  22. Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment (HTG713)

    Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people.

  23. Digital self-help for eating disorders: early value assessment (HTG768)

    Early value assessment (EVA) guidance on digital self-help for eating disorders.

  24. Type 2 diabetes in adults (QS209)

    This quality standard covers prevention of type 2 diabetes in adults (aged 18 and over) and care and treatment for adults with type 2 diabetes. It describes high-quality care in priority areas for improvement.

  25. Mental wellbeing at work (NG212)

    This guideline covers how to create the right conditions for mental wellbeing at work. It aims to promote a supportive and inclusive work environment, including training and support for managers and helping people who have or are at risk of poor mental health.

  26. Drug use disorders in adults (QS23)

    This quality standard covers assessment and treatment of drug use disorders in adults (aged 18 and over). It includes treating the misuse of opioids, cannabis, stimulants and other drugs in all settings, including inpatient and specialist residential and community-based treatment settings, and prison services. It describes high-quality care in priority areas for improvement.

  27. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184)

    This guideline covers investigating and managing gastro-oesophageal reflux disease (GORD) and dyspepsia in people aged 18 and over. It aims to improve the treatment of GORD and dyspepsia by making detailed recommendations on Helicobacter pylori eradication, and specifying when to consider laparoscopic fundoplication and referral to specialist services.

  28. Anxiety disorders (QS53)

    This quality standard covers identifying and managing anxiety disorders in adults, young people and children in primary, secondary and community care. It covers a range of anxiety disorders, including generalised anxiety disorder, social anxiety disorder, post-traumatic stress disorder, panic disorder, obsessive-compulsive disorder and body dysmorphic disorder. It describes high-quality care in priority areas for improvement.

  29. Digital technologies for managing non-specific low back pain: early value assessment (HTG712)

    Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over.

  30. Is contingency management effective in reducing alcohol consumption in people who misuse alcohol compared with standard care?

    even with the most effective current treatment (for example, cognitive behavioural therapies and social network and environment-based...

  31. Is acupuncture effective in reducing alcohol consumption compared with standard care?

    acamprosate or naltrexone) and psychological treatments (for example, cognitive behavioural therapies and social network and...

  32. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)

    NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .

  33. What is the comparative clinical and cost effectiveness of pharmacological and psychosocial interventions for anxiety disorders in autistic children and young people?

    young people? Any explanatory notes(if applicable) Early trials of CBT for anxiety in autistic children and young people have been...

  34. The role of parents in the treatment of children and young people with social anxiety disorder:- What is the best way of involving parents in the treatment of children and young people (at different stages of development) with social anxiety disorder?

    should be tested using an RCT design with standard care (for example, group CBT) as the comparison. It should report short- and...

  35. Atrial fibrillation: diagnosis and management (NG196)

    This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.

  36. Newly recommended CBT therapies could help children and young people deal with anxiety

    NICE conditionally recommends digital cognitive behaviour therapies (CBT) for use in the NHS to help children and young people with symptoms of mild to moderate anxiety

  37. Head injury (QS74)

    This quality standard covers assessment, early management and rehabilitation following head injury in adults, young people and children. It describes high-quality care in priority areas for improvement.

  38. Online help programme recommended for people with eating disorders

    An online therapy programme can be used to help people aged 16 and over with eating disorders whilst they wait for specialist NHS treatment, an independent NICE has said.

  39. Neonatal infection: antibiotics for prevention and treatment (NG195)

    This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.

  40. High-throughput non-invasive prenatal testing for fetal RHD genotype (HTG420)

    Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype.

  41. Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)

    Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.

  42. Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (NG202)

    This guideline covers the diagnosis and management of obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) and chronic obstructive pulmonary disease with OSAHS (COPD–OSAHS overlap syndrome) in people over 16. It aims to improve recognition, investigation and treatment of these related conditions.

  43. Supporting adult carers (NG150)

    This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.

  44. Decision-making and mental capacity (NG108)

    This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.

  45. Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)

    Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in adults with alcohol dependence.

  46. iFuse for treating chronic sacroiliac joint pain (HTG488)

    Evidence-based recommendations on iFuse for treating chronic sacroiliac joint pain.

  47. Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)

    Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.

  48. Daridorexant for treating long-term insomnia (TA922)

    Evidence-based recommendations on daridorexant (QUVIVIQ) for treating long-term insomnia in adults.